Medimmune stops arthritis and psoriasis trials

By Staff Writers
Tuesday, 31 August, 2004

Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.

The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

Content from other channels on our network

First cell-cultured food approved by FSANZ Board

Lifting the lid on the benefits of sodium reduction legislation

CSIRO program to help advance WA's agrifood innovations

The International Cake Show Australia opens in Brisbane

Mars Wrigley Australia invests $6.5m to expand capacity at its Asquith factory

Linux is coming!

Thermal mass flowmeters: when is pressure compensation important?

Welding body calls for a nation‍-‍building approach to combat Trump's tariffs

Mars Wrigley to boost Asquith factory with new production line

New free TAFE courses aim to develop manufacturing skills

Circularity needed at scale for Aust building industry

Textile recycler BlockTexx wins Gold for sustainability

Water shortages prompt Vic Government to boost supply

New chemistry extracts valuable compounds from plant waste

Coalition to scrap vehicle policy reducing emissions